General Dermatology

Explore the standout moments and expert insights from Dermatology Times' Cutaneous Connection podcast episodes in 2024.

Discover the most impactful insights and expert advice from Dermatology Times' 2024 Interview Intersection column.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies and clinical research from the year.

Find out what the top 10 most popular articles of 2024 were from Dermatology Times.

Catch up on coverage of FDA-approved drugs in the second half of 2024.

Explore the top dermatology news of 2024, highlighting breakthroughs, innovations, and key clinical insights shaping the future of skin care and treatment.

Catch up on coverage of FDA-approved drugs in the first half of 2024.

Dermatology Times is looking back on the top dermatology news headlines from 2024.

Dermatology Times is looking back on the top stories in dermatology that involve strides in skin health equity: addressing disparities for skin of color, women, LGBTQ+ patients, and improving care access.

These promising results align with what was discovered in the single-ascending dose portion of the trial earlier this year.

In case you missed it, this week we had news about tapinarof’s FDA approval in AD patients 2 and older, new ICD-10 codes for CCCA and FFA, a phase 2 study of INF904, and more.

Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a Dermatology Times custom video series.

Dermatology Times is looking back on the top stories in dermatology from the month of December.

Dermatology Times is recapping our top expert interviews from the month of December.

Experts in the field shared insights with Dermatology Times on what they found most innovative, educational, and helpful in the past year.

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.

Hawkes shared his excitement for the near future of dermatology, recognizing the increasing ability to provide tailored care to patients.

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Take a look back at this year's newly FDA-approved dermatology devices and drugs.

In case you missed it, this week we had news about the 308 nm excimer light and 2940 erbium laser for vitiligo, the new Diamond technique for the neck and décolleté, potential risk factors for developing CHE in China, and more.

Fall Editor in Chief Raj Chovatiya, MD, PhD, MSCI, celebrates the joy of diverse traditions and reflects on the path to equity in dermatology as we move toward a brighter 2025.

A reflection on 2024's dermatology advancements, from FDA approvals to expert insights, setting the stage for another transformative year in 2025.

In case you missed it, this week we had news about the FDA-approval of Yesintek for psoriasis treatment, APG777 clinical trial updates, our inaugural Horizons in Advanced Practice meeting, and more.

Certain dermoscopic features in cutaneous warts may be associated with a favorable cryotherapy response.

The algorithm demonstrated 81% accuracy, promising fast, reliable, and reproducible assessments for patients. 

Investigating podiatry students' diagnostic accuracy and reasoning for dermatological lesions across skin tones using a mixed-method research approach.

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Dermatology Times is recapping our top expert interviews from the month of November.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

Learn more about the in-depth topics covered in the November 2024 print issue of Dermatology Times.